Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.

Leukemia - 1 Jan 2019

Tasian Sarah K, Casas Jessica A, Posocco David, Gandre-Babbe Shilpa, Gagne Alyssa L, Liang Ge, Loh Mignon L, Weiss Mitchell J, French Deborah L, Chou Stella T

Abstract excerpt

Juvenile myelomonocytic leukemia (JMML) is an uncommon myeloproliferative neoplasm driven by Ras pathway mutations and hyperactive Ras/MAPK signaling. Outcomes for many children with JMML remain dismal with current standard-of-care cytoreductive chemotherapy and hematopoietic stem cell transplantation. We used patient-derived induced pluripotent stem cells (iPSCs) to characterize the signaling profiles and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Induced Pluripotent Stem Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myelomonocytic, Juvenile

Share to Neoplastic Stem Cells

Share to Protein Kinase Inhibitors

Share to Protein Kinases

Share to Signal Transduction

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 29884903
DOI: 10.1038/s41375-018-0169-y
PMCID: PMC6286697

Genes

CBL
PTPN11

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.PMID 29884903Read ↗

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemiaSemantic proximity Read ↗

Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.Semantic proximity Read ↗

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology GroupSemantic proximity Read ↗

Juvenile myelomonocytic leukemia: who’s the driver at the wheel?Semantic proximity Read ↗

Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?Semantic proximity Read ↗

Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL.Semantic proximity Read ↗

Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.Semantic proximity Read ↗

Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.Semantic proximity Read ↗

Juvenile myelomonocytic leukemia.Semantic proximity Read ↗

[Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].Semantic proximity Read ↗

Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.Semantic proximity Read ↗

Integrated molecular profiling of juvenile myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.